Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients
NCT ID: NCT00640328
Last Updated: 2017-04-11
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
38 participants
Study Classification
INTERVENTIONAL
Study Start Date
2008-05-31
Study Completion Date
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or Immunoglobulin G (IgG) levels.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
NCT01457924
Multiple Sclerosis
COMPLETED
PHASE2
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
NCT04878211
Relapsing Multiple Sclerosis (RMS)
TERMINATED
PHASE4
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
NCT06869785
Relapsing Multiple Sclerosis (RMS)
RECRUITING
PHASE3
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
NCT04486716
Relapsing Multiple Sclerosis
COMPLETED
PHASE3
Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab
NCT03249714
Relapsing Multiple Sclerosis
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The trial consists of two phases, a 48 week treatment period, followed by an individualized treatment period of up to two years.
Patients are treated in cohorts of increasing doses (100 mg, 300 mg and 700 mg) with 12 patients in each dose cohort. Within each cohort patients are randomized asymmetrically in a 2:1 ratio such that eight patients will receive ofatumumab and four patients will receive placebo. After 24 weeks the patients randomized to placebo will be treated with the active dose for the cohort. For blinding purposes, patients randomized to the active dose will be treated with placebo after 24 weeks. Thus, each patient will receive two administrations of trial product with 24 weeks follow-up resulting in a total treatment period of 48 weeks duration. An Independent Data Monitoring Committee (IDMC) will review and evaluate the safety data of each cohort, a minimum of 4 weeks data including the week 4 Magnetic Resonance Imaging (MRI) from at least 10 patients, to consider if progression to the next higher dose cohort is acceptable.
The trial product is administered as two infusions separated by two weeks. Clinical assessment and Gadolinium enhanced (Gd-enhanced) MRI scan will be performed at weeks -4, 0, 2, 4, and every 4 weeks until week 48. The MRI scan at week 2 is carried out for safety assessment prior to administering the second infusion in the first treatment course. When patients in all dose cohorts have been dosed and have had week 4 MRI scans performed, an IDMC will review all available safety data.
After completion of week 48 patients will be followed to monitor B-cell and IgG normalization. B-cell levels will be monitored every 12 weeks until CD19+ cells have returned to baseline level (Visit 3) or normalized level. If the B-cell levels are not normalized after two years the patient should be followed until either the IgG or the B-cell levels are normalized (see Section 9.2.4 for details). During this period Gd-enhanced MRI follow up scans will be performed every 12 weeks to evaluate potential rebound, safety and for Progressive Multifocal Leukoencephalopathy (PML) monitoring.
Patients are treated in cohorts of increasing doses (100 mg, 300 mg and 700 mg) with 12 patients in each dose cohort. Within each cohort patients are randomized asymmetrically in a 2:1 ratio such that eight patients will receive ofatumumab and four patients will receive placebo. After 24 weeks the patients randomized to placebo will be treated with the active dose for the cohort. For blinding purposes, patients randomized to the active dose will be treated with placebo after 24 weeks. Thus, each patient will receive two administrations of trial product with 24 weeks follow-up resulting in a total treatment period of 48 weeks duration. An Independent Data Monitoring Committee (IDMC) will review and evaluate the safety data of each cohort, a minimum of 4 weeks data including the week 4 Magnetic Resonance Imaging (MRI) from at least 10 patients, to consider if progression to the next higher dose cohort is acceptable.
The trial product is administered as two infusions separated by two weeks. Clinical assessment and Gadolinium enhanced (Gd-enhanced) MRI scan will be performed at weeks -4, 0, 2, 4, and every 4 weeks until week 48. The MRI scan at week 2 is carried out for safety assessment prior to administering the second infusion in the first treatment course. When patients in all dose cohorts have been dosed and have had week 4 MRI scans performed, an IDMC will review all available safety data.
After completion of week 48 patients will be followed to monitor B-cell and IgG normalization. B-cell levels will be monitored every 12 weeks until CD19+ cells have returned to baseline level (Visit 3) or normalized level. If the B-cell levels are not normalized after two years the patient should be followed until either the IgG or the B-cell levels are normalized (see Section 9.2.4 for details). During this period Gd-enhanced MRI follow up scans will be performed every 12 weeks to evaluate potential rebound, safety and for Progressive Multifocal Leukoencephalopathy (PML) monitoring.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Multiple Sclerosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
CROSSOVER
Primary Study Purpose
TREATMENT
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1.1
100mg ofatumumab then placebo
Group Type
EXPERIMENTAL
Ofatumumab 100
Intervention Type
DRUG
100mg
Placebo
Intervention Type
DRUG
matching placebo
Cohort 1.2
placebo then 100mg ofatumumab
Group Type
EXPERIMENTAL
Ofatumumab 100
Intervention Type
DRUG
100mg
Placebo
Intervention Type
DRUG
matching placebo
Cohort 2.1
300mg ofatumumab then placebo
Group Type
EXPERIMENTAL
Ofatumumab 300
Intervention Type
DRUG
300mg
Placebo
Intervention Type
DRUG
matching placebo
Cohort 2.2
placebo then 300mg ofatumumab
Group Type
EXPERIMENTAL
Ofatumumab 300
Intervention Type
DRUG
300mg
Placebo
Intervention Type
DRUG
matching placebo
Cohort 3.1
700mg ofatumumab then placebo
Group Type
EXPERIMENTAL
Ofatumumab 700
Intervention Type
DRUG
700mg
Placebo
Intervention Type
DRUG
matching placebo
Cohort 3.2
placebo then 700mg ofatumumab
Group Type
EXPERIMENTAL
Ofatumumab 700
Intervention Type
DRUG
700mg
Placebo
Intervention Type
DRUG
matching placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ofatumumab 100
100mg
Intervention Type
DRUG
Ofatumumab 300
300mg
Intervention Type
DRUG
Ofatumumab 700
700mg
Intervention Type
DRUG
Placebo
matching placebo
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with definite diagnosis of relapsing-remitting MS according to McDonald criteria
* Patients with:
* At least two confirmed relapses within the last 24 months or
* At least one confirmed relapse within the last 12 months or
* One confirmed relapse between 12 and 24 months prior to screening, and at least one documented T1 Gd-enhancing lesion on an MRI performed within 12 months prior to screening.
* Patients with disability equivalent to Expanded Disability Status Scale (EDSS) score of 0-5.0 (both included) at screening
* Neurologically stable patients with no evidence of relapse for at least 30 days prior to start of Screening and during the Screening Phase
* Female patients must be either post-menopausal, surgically incapable of bearing children or practicing an acceptable method of birth control e.g. hormonal contraceptives, intrauterine device, spermicide and barrier as long as they are on trial medication and for a period of 1 year following the last infusion of trial drug. Females of childbearing potential must have a negative pregnancy test at screening visit prior to entry into the treatment period
* Following receipt of verbal and written information about the trial, the patient must provide signed informed consent before any trial related activity is carried out.
* Patients with:
* At least two confirmed relapses within the last 24 months or
* At least one confirmed relapse within the last 12 months or
* One confirmed relapse between 12 and 24 months prior to screening, and at least one documented T1 Gd-enhancing lesion on an MRI performed within 12 months prior to screening.
* Patients with disability equivalent to Expanded Disability Status Scale (EDSS) score of 0-5.0 (both included) at screening
* Neurologically stable patients with no evidence of relapse for at least 30 days prior to start of Screening and during the Screening Phase
* Female patients must be either post-menopausal, surgically incapable of bearing children or practicing an acceptable method of birth control e.g. hormonal contraceptives, intrauterine device, spermicide and barrier as long as they are on trial medication and for a period of 1 year following the last infusion of trial drug. Females of childbearing potential must have a negative pregnancy test at screening visit prior to entry into the treatment period
* Following receipt of verbal and written information about the trial, the patient must provide signed informed consent before any trial related activity is carried out.
Exclusion Criteria
* Diagnosis of Secondary Progressive Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS) or Progressive Relapsing Multiple Sclerosis (PRMS) or Neuromyelitis optica
* Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML) or confirmed PML
* Findings on brain MRI scan indicating any other clinically significant brain abnormality other than MS
* Patients unable to undergo MRI scans (e.g. due to pacemaker, severe claustrophobia, hypersensitivity to contrast media) or who lack adequate peripheral venous access
* Patients who have had the following treatments:
* Lymphocyte-depleting therapies (e.g. alemtuzumab (Campath®), anti-Cluster of Differentiation (CD4), cladribine, total body irradiation, bone marrow transplantation), mitoxantrone or cyclophosphamide at any time
* Anti-CD20 treatments or any monoclonal antibodies at any time
* Immunoglobulin, azathioprine, cyclosporine, tacrolimus or other immunosuppressive agents, immunomodulatory agents or plasma exchange within six months prior to randomization in the trial apart from Glatiramer Acetate and Interferon Beta (IFN-b).
* Glatiramer Acetate or IFN-b within three months prior to the randomization in the trial.
* Glucocorticoids or Adrenocorticotropic Hormone (ACTH) within one month prior to the screening in the trial.
* Receipt of a live vaccine within one month prior to screening in the trial.
* Plasmapheresis for treatment of relapses within 2 months prior to randomization in the trial.
* Initiation of therapy with Statins or hormone replacement treatment within one month or less prior to screening in the trial.
* Patients who have received other disease modifying therapies for MS may be allowed on a case to case basis after discussion with the sponsors medical monitor
* Past or current history of medically significant adverse effects (including allergic reactions) from:
* Cetirizine
* Prednisolone
* Paracetamol/acetaminophen
* Plasma proteins or a known hypersensitivity to components of the investigational product.
* Past or current malignancy, except for
* Cervical carcinoma Stage 1B or less
* Non-invasive basal cell and squamous cell skin carcinoma
* Cancer diagnoses with a complete response of a duration of \> 5 years. Patients with a prior history of hematological malignancies are excluded regardless of response
* Clinically significant cardiac disease, including acute myocardial infarction within six months from screening, unstable angina, congestive heart failure, previous venous or arterial thrombosis or arrhythmia requiring therapy.
* Electrocardiogram (ECG) showing significant abnormality that the treating investigator determines may jeopardize the subject's health (i.e. acute ischemia, left bundle branch or bifascicular block)
* Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, immunodeficiency syndrome, pulmonary, cerebral, psychiatric or neurological disease which may impair their reliable participation in the trial or necessitate the use of medication not allowed by this protocol.
* History of severe, clinically significant Central Nervous System (CNS) trauma (e.g. cerebral contusion, spinal cord compression) or a history or presence of myelopathy due to spinal cord compression by disk or vertebral disease
* Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C. Any previous serious infections should be discussed with the sponsors medical monitor (e.g. opportunistic or atypical infections)
* Female patients who are pregnant or nursing.
* Use of an investigational drug or other experimental therapy for a condition other than MS within 4 weeks prior to screening. Any prior use of an investigational drug or other experimental therapy for MS at any time should be discussed with the medical monitor.
* Current participation in any other interventional clinical trial. Participation in non-interventional trial requires approval of the protocol by the sponsor
* Serum vitamin B12 below lower limit of normal
* Positive polymerase chain reaction (PCR) screening for John Cunningham Virus (JC Virus) as measured by qualitative plasma and/or white blood cell JCV DNA
* Serologic evidence of Hepatitis B (HB) infection based on the results of testing for Hepatitis B Surface Antigen (HBsAg), anti- Hepatitis B Core (HBc) and anti- Hepatitis B Surface (HBs) antibodies with eligibility based on the results as follows:
* Patients positive for HBsAg are excluded
* Patients negative for HBsAg but positive for both anti-HBc and anti-HBs antibodies (indicating past infection) are eligible
* Patients negative for HBsAg and anti-HBc antibody but positive for anti-HBs antibody (indicating past vaccination) are eligible
* Patients negative for HBsAg and anti-HBs antibody but positive for anti-HBc antibody will require clarification of their status by testing for HB DNA, which if positive will exclude the patient from participation
* Patient with documented vaccination against Hepatitis B (primary and secondary immunization and booster) will be considered eligible for the trial.
* Positive serology for HIV
* Screening laboratory values:
* White Blood Cell (WBC) \< 3.0 x 109/L
* Neutrophils \< 2 x 109/L
* Platelets \< 100 x 109/L
* Circulating IgG level \< lower limit of normal (according to central laboratory range)
* Serum Alanine Aminotransferase (S-ALAT) \> 2.5 times the upper limit of normal (according to central laboratory range)
* Serum Alpha Fetoprotein (S-AP) \> 2.0 times the upper limit of normal (according to central laboratory range)
* Serum Aspartate Aminotransferase (ASAT) \>3.0 times the upper limit of normal (according to central laboratory range)
* Bilirubin \> 1.5 times the upper limit of normal (according to central laboratory range)
* S-creatinine \> the upper limit of normal (according to central laboratory range)
* CD4 count \<500 cells/mm3, CD4:CD8 \<0.9
* Patients known or suspected of not being able to comply with a trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder).
* Positive test for Hepatitis C antibody confirmed with a Hepatitis C real time (RT) PCR assay.
Patients who are positive for Hepatitis C antibody and negative when the Hepatitis C RT PCR assay is performed will be eligible for the study. Patients who are positive for Hepatitis C antibody and have a positive or indeterminate result when the Hepatitis C RT PCR assay is performed will not be eligible for the study.
* Positive test results for tuberculosis using the QuantiFERON test and/or Chest X-ray findings suggestive of tuberculosis (TB). For patients who have had a Chest X-ray performed within the past 6 months without any findings indicative of TB, QuantiFERON test alone may be performed.
* Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML) or confirmed PML
* Findings on brain MRI scan indicating any other clinically significant brain abnormality other than MS
* Patients unable to undergo MRI scans (e.g. due to pacemaker, severe claustrophobia, hypersensitivity to contrast media) or who lack adequate peripheral venous access
* Patients who have had the following treatments:
* Lymphocyte-depleting therapies (e.g. alemtuzumab (Campath®), anti-Cluster of Differentiation (CD4), cladribine, total body irradiation, bone marrow transplantation), mitoxantrone or cyclophosphamide at any time
* Anti-CD20 treatments or any monoclonal antibodies at any time
* Immunoglobulin, azathioprine, cyclosporine, tacrolimus or other immunosuppressive agents, immunomodulatory agents or plasma exchange within six months prior to randomization in the trial apart from Glatiramer Acetate and Interferon Beta (IFN-b).
* Glatiramer Acetate or IFN-b within three months prior to the randomization in the trial.
* Glucocorticoids or Adrenocorticotropic Hormone (ACTH) within one month prior to the screening in the trial.
* Receipt of a live vaccine within one month prior to screening in the trial.
* Plasmapheresis for treatment of relapses within 2 months prior to randomization in the trial.
* Initiation of therapy with Statins or hormone replacement treatment within one month or less prior to screening in the trial.
* Patients who have received other disease modifying therapies for MS may be allowed on a case to case basis after discussion with the sponsors medical monitor
* Past or current history of medically significant adverse effects (including allergic reactions) from:
* Cetirizine
* Prednisolone
* Paracetamol/acetaminophen
* Plasma proteins or a known hypersensitivity to components of the investigational product.
* Past or current malignancy, except for
* Cervical carcinoma Stage 1B or less
* Non-invasive basal cell and squamous cell skin carcinoma
* Cancer diagnoses with a complete response of a duration of \> 5 years. Patients with a prior history of hematological malignancies are excluded regardless of response
* Clinically significant cardiac disease, including acute myocardial infarction within six months from screening, unstable angina, congestive heart failure, previous venous or arterial thrombosis or arrhythmia requiring therapy.
* Electrocardiogram (ECG) showing significant abnormality that the treating investigator determines may jeopardize the subject's health (i.e. acute ischemia, left bundle branch or bifascicular block)
* Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, immunodeficiency syndrome, pulmonary, cerebral, psychiatric or neurological disease which may impair their reliable participation in the trial or necessitate the use of medication not allowed by this protocol.
* History of severe, clinically significant Central Nervous System (CNS) trauma (e.g. cerebral contusion, spinal cord compression) or a history or presence of myelopathy due to spinal cord compression by disk or vertebral disease
* Chronic or ongoing active infectious disease requiring systemic treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C. Any previous serious infections should be discussed with the sponsors medical monitor (e.g. opportunistic or atypical infections)
* Female patients who are pregnant or nursing.
* Use of an investigational drug or other experimental therapy for a condition other than MS within 4 weeks prior to screening. Any prior use of an investigational drug or other experimental therapy for MS at any time should be discussed with the medical monitor.
* Current participation in any other interventional clinical trial. Participation in non-interventional trial requires approval of the protocol by the sponsor
* Serum vitamin B12 below lower limit of normal
* Positive polymerase chain reaction (PCR) screening for John Cunningham Virus (JC Virus) as measured by qualitative plasma and/or white blood cell JCV DNA
* Serologic evidence of Hepatitis B (HB) infection based on the results of testing for Hepatitis B Surface Antigen (HBsAg), anti- Hepatitis B Core (HBc) and anti- Hepatitis B Surface (HBs) antibodies with eligibility based on the results as follows:
* Patients positive for HBsAg are excluded
* Patients negative for HBsAg but positive for both anti-HBc and anti-HBs antibodies (indicating past infection) are eligible
* Patients negative for HBsAg and anti-HBc antibody but positive for anti-HBs antibody (indicating past vaccination) are eligible
* Patients negative for HBsAg and anti-HBs antibody but positive for anti-HBc antibody will require clarification of their status by testing for HB DNA, which if positive will exclude the patient from participation
* Patient with documented vaccination against Hepatitis B (primary and secondary immunization and booster) will be considered eligible for the trial.
* Positive serology for HIV
* Screening laboratory values:
* White Blood Cell (WBC) \< 3.0 x 109/L
* Neutrophils \< 2 x 109/L
* Platelets \< 100 x 109/L
* Circulating IgG level \< lower limit of normal (according to central laboratory range)
* Serum Alanine Aminotransferase (S-ALAT) \> 2.5 times the upper limit of normal (according to central laboratory range)
* Serum Alpha Fetoprotein (S-AP) \> 2.0 times the upper limit of normal (according to central laboratory range)
* Serum Aspartate Aminotransferase (ASAT) \>3.0 times the upper limit of normal (according to central laboratory range)
* Bilirubin \> 1.5 times the upper limit of normal (according to central laboratory range)
* S-creatinine \> the upper limit of normal (according to central laboratory range)
* CD4 count \<500 cells/mm3, CD4:CD8 \<0.9
* Patients known or suspected of not being able to comply with a trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder).
* Positive test for Hepatitis C antibody confirmed with a Hepatitis C real time (RT) PCR assay.
Patients who are positive for Hepatitis C antibody and negative when the Hepatitis C RT PCR assay is performed will be eligible for the study. Patients who are positive for Hepatitis C antibody and have a positive or indeterminate result when the Hepatitis C RT PCR assay is performed will not be eligible for the study.
* Positive test results for tuberculosis using the QuantiFERON test and/or Chest X-ray findings suggestive of tuberculosis (TB). For patients who have had a Chest X-ray performed within the past 6 months without any findings indicative of TB, QuantiFERON test alone may be performed.
Minimum Eligible Age
18 Years
Maximum Eligible Age
55 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
115102
Identifier Type: -
Identifier Source: org_study_id
NCT01526993
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
NCT04847596
COMPLETED
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
NCT02637856
COMPLETED
PHASE3
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
NCT04667117
COMPLETED
PHASE4
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS
NCT04788615
COMPLETED
PHASE3
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
NCT07189325
NOT_YET_RECRUITING
PHASE3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114
ACTIVE_NOT_RECRUITING
PHASE3
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
NCT00097188
COMPLETED
PHASE2
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
NCT02792218
COMPLETED
PHASE3
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
NCT03737851
COMPLETED
PHASE2
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281
RECRUITING
PHASE3
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
NCT06460324
COMPLETED
A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis
NCT00035529
TERMINATED
PHASE2
A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting
NCT03589105
COMPLETED
PHASE4
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248
RECRUITING
PHASE2
An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01578785
TERMINATED
PHASE3
Effectiveness of Ofatumumab in Real-world Practice
NCT06760624
COMPLETED
Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
NCT06167642
ENROLLING_BY_INVITATION
Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis
NCT06644638
COMPLETED
A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01808482
TERMINATED
PHASE1
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
NCT06737419
COMPLETED
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
NCT04711148
ACTIVE_NOT_RECRUITING
PHASE2
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
NCT01405820
COMPLETED
PHASE2
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
NCT03085810
TERMINATED
PHASE3